Open AccessDendritic cell vaccination in glioblastoma after fluorescence-guided resection
Author(s) -
Ricardo Díez Valle
Publication year - 2012
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v3.i11.142
Subject(s) - medicine , temozolomide , immunotherapy , discontinuation , bevacizumab , chemotherapy , vaccination , oncology , surgery , active immunotherapy , glioblastoma , cancer , immunology , cancer research
To assess whether the addition of a customized, active immunotherapy to standard of care including fluorescence-guided surgery, may provide hints of an improved survival for patients with poor-prognosis, incurable glioblastoma multiform.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom